FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
What happened
FDA reviewed the website https://maneandsteel.com in August 2025 and found it offers compounded drug products, including semaglutide. FDA cited website claims such as 'Clinically Proven Weight Loss' and 'Clinically proven GLP-1 therapy' as false or misleading because compounded drugs are not FDA-approved, making the products misbranded (falsely or misleadingly labeled or promoted).
What FDA found
The website's claim 'Clinically Proven Weight Loss' for compounded semaglutide was false or misleading because the product is not FDA-approved.
FDCA section 502(a) [21 U.S.C. § 352(a)]The claim that the therapy is 'clinically proven' to suppress appetite, regulate blood sugar, and accelerate fat loss implied the compounded product was the same as an FDA-approved product.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA said the advertising or promotion of the compounded semaglutide was false or misleading, which makes the compounded drug misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The misbranded compounded semaglutide was introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days of receipt, send OCQC in CDER's Office of Compliance a written response describing specific steps taken to address the violations and prevent recurrence, with supporting documents. If you cannot finish within that time, state the reason and your planned timeline.
Who should pay attention
- telehealth and online weight-loss drug sellers
- compounders and pharmacies selling semaglutide
- marketing teams making 'clinically proven' claims for compounded drugs
This is a summary. Read the original letter on fda.gov.